In March 2026, the FDA did something it hadn’t done since before most supplement buyers were born: it held a public meeting to ask whether the law that governs the supplement industry still works.
That law, the Dietary Supplement Health and Education Act of 1994 - DSHEA - created the framework under which supplements are sold in the United States. And for more than three decades, it stayed mostly untouched. Now, within a single year, the agency is publicly questioning its scope, drafting rules that could affect thousands of products, and signaling that the era of light oversight may be ending.
But that’s not the only thing shifting. A category of supplements that didn’t exist three years ago - products marketed to people taking GLP-1 weight-loss drugs - has grown into a $4.1 billion market. Social media, in less than five years, has overtaken search engines as the way younger consumers discover supplements. And women’s health has become the fastest-growing segment in the industry.
Put together, 2026 is shaping up to be the most consequential year for supplements since DSHEA itself. Here’s what’s changing, why it matters, and what it means for what ends up on your shelf.
The regulatory floor is shifting#
The FDA’s March 27, 2026 public meeting wasn’t a rulemaking session - nothing was voted on or enacted. But the fact that the agency convened it at all is significant. According to law firm Alston & Bird’s analysis, the meeting explored whether DSHEA’s definition of a “dietary ingredient” can accommodate technologies that didn’t exist in 1994: precision fermentation, cell-cultured compounds, recombinant proteins. The subtext, as one industry lawyer told NutraIngredients, is that 2026 “could be the biggest year for dietary supplements since the introduction of GMPs” in 2007.
The most concrete change in progress involves the self-affirmed GRAS pathway - “Generally Recognized As Safe.” Right now, companies can decide on their own that an ingredient is safe and start selling it without telling the FDA. The agency is drafting rules that would require companies to submit safety data for ingredients they currently self-certify. Ivan Wasserman, a partner at Amin Wasserman Gurnani who spoke with NutraIngredients, estimated that roughly 10,000 ingredients currently on the market could be affected.
And whether the rule gets finalized in its current form? That’s uncertain - as of mid-2026, nothing had been published in the Federal Register. But the direction is clear, and the industry is responding.
Other pressure points are stacking up too. State-level age restrictions on weight-loss and muscle-building supplements are already active in New York, and similar bills are advancing in Michigan, Illinois, Massachusetts, and New Jersey, according to a January 2026 analysis by law firm Skadden, Arps. Meanwhile, the “Make America Healthy Again” movement is pushing companies to remove artificial dyes and synthetic additives - not because Washington told them to, but because consumer expectations have shifted enough to make it a business imperative. And major retailers - Walmart, Target, CVS - are setting their own proprietary ingredient standards that brands must meet to keep shelf space, effectively acting as regulators in the absence of clear federal rules. Not the system anyone designed, but it’s the one that’s emerging.
So what does this mean if you’re just someone who buys supplements? The aisle is likely to look different within a few years. Some products may disappear. Others will carry more transparency about what’s in them. The era of unverified self-certification appears to be closing - and honestly, that’s not a bad thing.
Ozempic was supposed to shrink the supplement industry. It did the opposite.#
Walk into a GNC or Vitamin Shoppe right now and you’ll see entire shelf sections that weren’t there two years ago, rebranded around “GLP-1 support.” When drugs like Ozempic, Wegovy, and Mounjaro began their rapid adoption, a reasonable assumption was that weight-loss supplements would suffer. Why buy a supplement for appetite suppression when a prescription drug does it more effectively?
But instead of shrinking, an entirely new supplement category emerged. The market for products supporting GLP-1 users - protein powders, fiber supplements, electrolyte formulations, multivitamins targeting specific deficiencies - was estimated at $4.1 billion in 2025, according to Future Market Insights, with a projected growth rate of 12.2 percent annually. That’s a whole industry built around a problem nobody was talking about three years ago.
The reason isn’t complicated. These drugs have well-documented problems, and the supplement industry rushed in to solve them. A scientific roundtable convened by WSRO in March 2026 reported that 65 percent of GLP-1 users stop within one year - and 85 percent stop within two - driven by cost, side effects, or both. Among those who stay on them, 25 to 39 percent of the weight they lose may be lean mass rather than fat, according to the same roundtable. Specific nutrient deficiencies show up too: vitamin D, iron, thiamine, calcium, magnesium, potassium - common enough that GNC has started tracking them in its customer data, as NutraIngredients reported.
The supplement industry’s response has coalesced around three pillars: protein (to preserve muscle), fiber (those gastrointestinal side effects are the number one reason people quit), and hydration (electrolytes, since food and water intake both drop). Mintel data cited by NutraIngredients identifies these as the three biggest opportunities in the GLP-1 support category.
Worth knowing: there’s a regulatory boundary here. Terms like “natural GLP-1” and “faux-zempic” - which several brands have used to suggest their products do what the drugs do - are already prohibited in the EU and UK. NutraIngredients reports similar enforcement is expected in the US. No supplement on the market meaningfully replicates GLP-1 receptor activation. Products that claim otherwise should raise a red flag. And if you’re currently taking a GLP-1 medication and thinking about adding supplements, talk to your prescribing doctor first - the interaction landscape isn’t well studied, and the risks of unintended effects are real.
Your supplement routine used to come from your doctor. Now it comes from your feed.#
The way people discover supplements has undergone a structural shift, and it happened fast. In 2026, for the first time, consumers aged 18 to 34 rated creator content as more trustworthy than search engine results for health information, according to Nielsen data. Overall trust in influencers hit 67 percent - up from 61 percent in 2025 - and health and wellness micro-influencers reached 81 percent trust rates for long-form product reviews. (Whether they should trust influencers that much is a different conversation - but the numbers are what they are.)
TikTok Shop has become a measurable, material sales channel for supplements. Nutrition Business Journal published its first-ever Social Commerce Report in 2026, and platform-specific data from Revuze shows category-level growth that would have been unthinkable five years ago. The old model - Google a symptom, read a blog, buy a bottle - is being replaced by a feed-driven funnel where the discovery, the explanation, and the purchase all happen inside the same app.
So here’s the obvious concern. Social media influencers aren’t medical professionals, and their supplement recommendations often reflect sponsorship arrangements rather than evidence review. That doesn’t mean every influencer recommendation is bad. But a recommendation from someone with a ring light isn’t the same thing as a recommendation from someone with a medical license. Treat them accordingly.
Alongside the social shift, personalization is maturing fast. The market for supplements tailored to individual test results, DNA data, or lifestyle questionnaires was valued at roughly $13.4 billion in 2025 by the Business Research Company, growing at 12.8 percent annually. The AI-driven subsegment is growing even faster: InsightAce Analytic projects it’ll expand from $1.6 billion in 2025 to nearly $18 billion by 2035 - a 27.4 percent annual growth rate.
The tech driving this ranges from AI engines using your purchase history and health quizzes to at-home microbiome kits and nutrigenomics panels. For younger consumers - Millennials and Gen Z - the subscription-based, individualized model is becoming the default expectation, according to investment bank Brown Gibbons Lang. Supplements as a service, basically.
Women’s health is the fastest-growing category, and it isn’t close#
At the supplement industry’s biggest trade event - Natural Products Expo West in Anaheim, March 2026 - women’s health was the hottest category. The global market for women’s health and beauty supplements reached an estimated $57.4 billion in 2024 and is projected to hit $77.5 billion by 2030, according to VitaQuest.
The growth areas tell you exactly where the demand is: perimenopause and menopause products are seeing explosive growth, along with fertility nutrition, prenatal and postnatal formulations, hormonal balance supplements, and bone density support. There’s a “femtech” crossover happening too - digital health tools and apps are increasingly driving demand for personalized supplement regimens targeting women’s health.
At Expo West this year, the shift was visible on the exhibit floor: perimenopause and menopause brands that occupied a handful of booths five years ago now anchor entire pavilions. Brown Gibbons Lang’s 2026 sector analysis names women’s health as the single biggest growth driver across the entire VMS market - not a subcategory, but the category. For a sector that treated women’s health as an afterthought for decades, the pivot isn’t just noticeable. It’s reshaping where product development dollars go.
This isn’t a niche. Grand View Research puts the total US supplement market at $68.7 billion in 2025, and no segment within it is growing faster than products aimed at women. The investment - and the shelf space - are finally catching up to the demand.
Here’s the catch: quality is still uneven#
For all the growth and innovation, basic quality control remains a problem. In March 2026, independent testing organization ConsumerLab published results showing that 32 percent of multivitamin products it tested failed to meet quality standards - label accuracy, dosage consistency, contamination. Separately, NutraIngredients reported that roughly half of creatine gummy products fail label claims, largely because creatine is chemically unstable in gummy form. (Creatine gummies were one of the fastest-growing formats in 2025, which we covered in our companion piece on supplement ingredient trends.)
This doesn’t mean supplements are dangerous, and it doesn’t mean the industry is collapsing. Most products pass testing. But it does mean that consumers who don’t check for independent certification are effectively gambling on what’s in the bottle.
The practical defense is straightforward: look for a seal from one of the major third-party certification programs - NSF International, USP (United States Pharmacopeia), or ConsumerLab. These organizations test for whether what’s on the label is actually in the bottle, in the amounts claimed, without harmful contaminants. None of them guarantee a product works for a given health purpose. They do verify that it’s what it says it is. In an industry where nearly one in three multivitamins failed the most recent ConsumerLab round, that matters more than most people realize.
What this means if you buy supplements#
The supplement industry isn’t going anywhere - the global market was $209.5 billion in 2025 and Grand View Research projects it’ll nearly double by 2033 - but how it operates is changing on multiple fronts at the same time.
More regulatory scrutiny means more products will eventually be backed by actual safety data. The GLP-1 ecosystem means supplements are increasingly being developed for specific medical contexts, not just general wellness. Social commerce and AI personalization mean the discovery process is faster and more individually targeted than ever. And the women’s health boom means a category that was underprioritized for decades is finally getting serious investment.
DSHEA was written in 1994 for a supplement industry that barely resembles today’s. The rulebook is being rewritten - not just by the FDA, but by the market forces, consumer expectations, and retail standards described above. The aisle is changing. The questions worth asking haven’t: is it third-party tested, does it contain what the label says, and have you discussed it with a healthcare professional who knows your full medical picture?
Disclaimer: This article provides market trend and industry information. It does not provide medical advice. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. Readers taking prescription medications - including GLP-1 drugs - should consult their prescribing physician before adding supplements. Pregnant or breastfeeding individuals, and those with chronic health conditions, should discuss supplement use with a qualified healthcare professional.
